Business Context and Reporting Period
This Form 8-K Current Report was filed by Pacific Biosciences of California, Inc. (PACB) on January 8, 2021. The report discloses the appointment of two new executive officers effective January 8, 2021, following a Board of Directors decision on December 31, 2020.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. This report focuses exclusively on executive compensation and appointments.
Material Changes
The primary material change is the addition of two senior executives from a competitor, Illumina, Inc., to the Company's leadership team:
- Mark Van Oene: Appointed Chief Operating Officer (COO) and designated principal operating officer.
- Peter Fromen: Appointed Chief Commercial Officer (CCO).
Compensation and Equity Details
The filing details the following compensation packages for the new appointees:
| Executive | Base Salary | Signing Bonus | Target Bonus | Stock Options | Restricted Stock Units (RSUs) |
|---|---|---|---|---|---|
| Mark Van Oene | $550,000 | $200,000 | 60% of base | 750,000 shares | 335,000 shares |
| Peter Fromen | $425,000 | $125,000 | 50% of base | 320,000 shares | 160,000 shares |
Severance and Change in Control: Both executives are eligible for severance agreements providing 12 months of base salary and COBRA coverage upon termination without cause or resignation for good reason. In the event of a change in control followed by termination, they are entitled to 100% acceleration of unvested equity, a lump sum equal to their annualized base salary (prorated), and a prorated target bonus.
Investor Verification Checklist
- Verify the vesting schedules for the granted stock options (25% at 1-year anniversary, then monthly) and RSUs (25% annually).
- Confirm the total dilution impact of the 1,365,000 new stock options and 495,000 new RSUs granted.
- Review the full text of the offer letters and severance agreements, which are filed as exhibits to the Form 10-K for the year ended December 31, 2020.
- Assess the strategic implications of hiring senior leadership from Illumina, a direct competitor in DNA sequencing systems.